<DOCUMENT>
<TYPE>EX-10.67
<SEQUENCE>12
<FILENAME>a2105973zex-10_67.txt
<DESCRIPTION>EXHIBIT 10.67
<TEXT>
<PAGE>

                                                              Exhibit 10.67



                             CONFIDENTIAL TREATMENT

                                 AMENDMENT NO. 2

                                     to the

                       MANUFACTURING AND SUPPLY AGREEMENT

                      entered into as of September 30, 2001

                                 by and between

                ACS DOBFAR, SPA AND CUBIST PHARMACEUTICALS, INC.

         This AMENDMENT NO. 2 ("AMENDMENT NO. 2"), to that certain Manufacturing
and Supply Agreement (the "AGREEMENT") entered into as of September 30, 2001, is
made this 12th day of February, 2003, by and between ACS Dobfar, SpA, an Italian
corporation ("ACSD") and Cubist Pharmaceuticals, Inc., a Delaware corporation
("CUBIST"). Unless otherwise defined herein, capitalized terms used but not
defined herein shall have the meaning set forth in the Agreement, and the
Agreement shall be amended to incorporate any additional definitions provided
for in this Amendment No. 1, including definitions in the preamble and recitals
hereto.

         WHEREAS, Cubist and ACSD desire to amend the Agreement as set forth in
this Amendment No. 1;

         NOW, THEREFORE, in consideration of the foregoing and the mutual
promises made herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree to
amend the Agreement as follows:

         1. AMENDMENT OF SECTION 2.1. The Agreement is hereby amended by
deleting Section 2.1 thereof in its entirety and replacing it with the following
Section 2.1:

         2.1      FACILITY CONSTRUCTION AND TIMETABLE

                  (a) By [*] (the FACILITY COMPLETION TARGET DATE), ACSD will
         construct, equip, test and qualify (IQ/OQ/PQ) and make operational the
         Facility in accordance with current Good Manufacturing Practices.

         ACSD's obligations hereunder include, but are not limited to:

                  (i)      [*] necessary to perform the Process in a dedicated
                           Facility;

                  (ii)     provision of [*] for [*] of [*];

                  (iii)    the [*] of all required [*] for the [*] of Product
                           and [*]: and

                  (iv)     [*] to manufacture Product.

         Subject to adjustment in accordance with Section 2.2, ACSD will
         complete all activities and to meet all dates set forth in this
         Agreement. ACSD agrees that the following events (the "Targets") shall
         occur by [*]: (i) ACSD shall produce [*] full [*] of the Facility; (ii)
         [*] thereto shall be completed and ready for [*]; (iii) ACSD shall
         commence [*]; and (iv) ACSD will be prepared in all respects for a [*].
         The target date for [*] of the NDA Manufacturing Supplement for [*] is
         [*]. In addition, ACSD shall (i) complete [*] and validation of [*] by
         [*]; and (ii) complete



*CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
 WITH THE COMMISSION


<PAGE>

                                       2


         theconsistency batches, the IQ/OQ/PQ, and the [*] validation batches
         for the purification process by [*]. ACSD agrees that time is of the
         essence in completing the tasks set forth in this Section 2.1 in order
         to comply with ACSD's obligation to supply Product in [*]. In
         connection with ACSD completing all activities required to meet the
         aforementioned dates, Cubist shall remit to ACSD [*] of [*] on each of
         (i) the date of execution by both parties of this Amendment No. 2 (the
         "February Payment"); (ii)May 1, 2003 (the "May Payment"); and (iii)
         August 1, 2003 (the "August Payment").

                  (b) By March 1, 2003, ACSD and Cubist shall mutually agree
         upon a schedule for all tasks [*] set forth in section 2.1(a) above
         (the "Schedule"). In the event that, in Cubist's sole discretion,
         Cubist determines that the Schedule will not enable [*], the May and
         August Payments shall not be payable to ACSD and ACSD shall promptly
         refund to Cubist the February Payment.

         2. AMENDMENT OF SECTION 3.2. The Agreement is hereby amended by
deleting Section 3.2 thereof in its entirety and replacing it with the following
Section 3.2:

         3.2      PROCESS VALIDATION

         ACSD will [*] a validation process at the Facility in accordance with
         EXHIBIT D herein, and at ACSD expense. [*] and limits for the process
         must span the [*] and limits [*] during the manufacture of [*] at [*].
         No Process changes will be made during the period beginning on [*] and
         ending on the [*]. All post-validation process changes must be approved
         by Cubist in writing. Cubist will provide [*] and [*] as such reports
         become available. ACSD will provide Cubist with a [*]* for the Facility
         and Process.

         3. AMENDMENT OF SECTION 3.3. The Agreement is hereby amended by
deleting Section 3.3 thereof in its entirety and replacing it with the following
Section 3.3:

         3.3      PROCESS IMPROVEMENTS

         Following the [*] of the date of the Facility Approval, ACSD may
         continue operating [*] Process improvements [*]. No Process
         improvements will be made during the period beginning on [*] and ending
         on the [*]. [*] for the purpose of [*] will be entirely at [*]. ACSD
         will reimburse Cubist for any additional Cubist expenses [*]. All [*]
         related to the [*] will be implemented only after [*]. The
         authorization will be obtained in writing following a successful and
         complete [*] outlined in the [*].

         4. AMENDMENT OF SECTION 3. The Agreement is hereby amended by adding
the following Section 3.5 immediately following the end of Section 3.4 of the
Agreement



*CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
 WITH THE COMMISSION



<PAGE>


                                       3


3.5      Q.A. DIRECTOR

         In order to ensure and maintain consistent quality assurance with
         respect to the Product and the process, on or before April 1, 2003 ACSD
         shall have hired, with the approval of Cubist (which approval shall not
         be unreasonably withheld), a full-time Quality Assurance Director and
         shall engage an independent validation consultant, each with
         significant experience in the process of manufacturing and supply of
         pharmaceutical products.

         5. AMENDMENT OF SECTION 5.1. The Agreement is hereby amended by
deleting Section 5.1 thereof in its entirety and replacing it with the following
Section 5.1:

         5.1      PURCHASE COMMITMENT

         Contingent upon the [*], Cubist will purchase a [*] kilograms of
         Product during the term of this Agreement, [*] and further subject to
         the [*]. In the event that the [*], or the [*], Cubist shall not be
         required to purchase [*] kg of Product [*] or in any other year during
         the term of the Agreement. Notwithstanding anything to the contrary
         herein, ACSD will [*] to be delivered in the year [*] and, if longer,
         the [*], in accordance with the commercial Process specified in the
         Exhibits B-1, C-1 and D herein which may be modified in writing by
         Cubist from time to time. To the extent that there is any conflict
         between the [*] set forth in Exhibit C-1 and those set forth in Exhibit
         B-1, the [*] set forth in Exhibit C-1 shall supersede in all respects.
         During the period prior to the receipt of Product Approvals, Cubist [*]
         in accordance with EXHIBITS B-1, C-1, and D herein. Any such Product
         purchases shall count toward the [*] kilograms of Product that Cubist
         is required to purchase. Subject to the conditions of this Agreement,
         Cubist agrees to make the following yearly purchases:

                   YEAR                PURCHASE MINIMUM(KG)

                   2004                [*]

                   2005                [*]

                   2006                [*]

                   2007                [*]

                   2008                [*]

                   2009                [*]

                   2010                [*]

                                       [*]

         The above schedule will be extended for any delays caused by ACSD.



*CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
 WITH THE COMMISSION



<PAGE>

                                       4



6. AMENDMENT OF SECTION 5.6. The Agreement is hereby amended by deleting Section
5.6(a) in its entirety and replacing it with the following Section 5.6(a)
5.6 OBLIGATION TO SUPPLY

(a)      [*] for Product submitted by Cubist [*], provided that such
         request is delivered to ACSD at least [*] days prior to the
         beginning of the corresponding quarter. ACSD shall not be in
         breach of this Section 5.6 if [*]. Delivery dates will be set
         independently from Product release and invoice dates as described
         in Section 5.7;

         7. AMENDMENT OF SECTION 6.1. The Agreement is hereby amended by
deleting Section 6.1 thereof in its entirety and replacing it with the following
Section 6.1:

         6.1      PRODUCT PRICE

                  (a)      Subject to the provisions of Sections 5, 6 and 7,
                           Cubist will [*], including the additional [*] kg
                           required to be purchased by Cubist in [*], at a price
                           of [*] per kilogram (USD [*]/kg);

         8. AMENDMENT OF SECTION 6.2. The Agreement is hereby amended by
deleting Section 6.2 thereof in its entirety and replacing it with the following
Section 6.2:

         6.2      PRODUCT PRICE [*]

         Cubist will pay ACSD [*] per kilogram (USD [*]) on the [*] purchased
         over the life of the contract other than the [*] kgs of Product [*] in
         [*] until cumulative [*] payments equal [*] (USD [*]). Once the
         cumulative [*] payments have accrued to [*](USD [*]), Cubist will
         immediately stop paying the [*] and will pay [*] per kilogram (USD
         [*]/kg) of Product, as provided in Section 6.1 herein.

                  YEAR                        PURCHASE MINIMUM            [*]

                  2005                        [*]                         [*]

                  2006                        [*]                         [*]

                  2007                        [*]                         [*]

                  2008                        [*]                         [*]




*CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
 WITH THE COMMISSION



<PAGE>

                                       5



                  2009                        [*]                         [*]

                  2010                        [*]                         [*]

                                                                          [*]

         The above schedule will be [*]. In the event that Cubist [*] as
         provided in Section 5.1, Cubist will pay [*] corresponding to the [*]
         in the year specified in this Section 6.2. Any delays [*] (including,
         but not limited, to [*]) will extend [*].

         9. AMENDMENT OF SECTION 7. The Agreement is hereby amended by deleting
Section 7 thereof in its entirety and replacing it with the following Section 7:

7.       EXCLUSIVITY

         ACSD covenants that it will not promote, sell, deliver or provide any
         Product or Daptomycin to any third party without the prior written
         consent of Cubist, or produce any product, bulk drug substance or
         active pharmaceutical ingredient [*] other than the Product.
         Notwithstanding the foregoing, ACSD shall be permitted to produce
         vancomycin (the "Competing Product") in the Facility for Eli Lilly &
         Company, provided that the following conditions have been and continue
         to be met at all times:

         (i)  ACSD [*] and as well as [*];

         (ii) ACSD [*] in accordance with the [*] in Cubist's Purchase Orders;

         (iii) ACSD, [*] in accordance with [*]; and

         (iv) At Cubist's request, [*], dedicated [*].

         In the event that any of conditions (i) through (iv) are not met, ACSD
         shall lose its right to produce the Competing Product and shall cease
         production thereof upon receipt of written notice from Cubist.

         10. AMENDMENT OF SECTION 12.1. The Agreement is hereby amended by
deleting Section 12.1 thereof in its entirety and replacing it with the
following Section 12.1:

         12.1     TERM

         This Agreement shall take effect as of the Effective Date and shall
         remain in effect until the seventh anniversary of Facility Approval or
         until ACSD has received all payments due under Section 6.2 unless
         sooner terminated in accordance with Section 12.2 or extended in
         accordance with this Section 12.1. Thereafter, this Agreement shall
         automatically renew for additional two-year terms. Not later than the
         sixth (6h) anniversary of the Effective Date, Cubist shall notify ACSD
         in writing whether Cubist desires to extend the Agreement for an
         additional two years. All



*CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
 WITH THE COMMISSION


<PAGE>

                                       6


         applicable terms and conditions of this Agreement shall remain in
         effect during such extension term, unless expressly amended in writing
         by the parties. Cubist may renew this Agreement for additional two-year
         extension terms by providing written renewal notice to ACSD not later
         than twelve (12) months prior to the expiration of the then current
         extension term.

         11. AMENDMENT OF SECTION 12.2. The Agreement is hereby amended by
adding the following Section 12.2(c) immediately following Section 12.2(b) of
the Agreement:

                  (c) In the event that any current Cubist supplier of Product
purchases substantially all of the stock or assets relating to that portion of
ACSD's business that is related to the subject of this Agreement, all payments
hereunder shall be promptly returned to Cubist and Cubist shall have the right
to modify any Purchase Requirements set forth herein. Cubist shall also have the
right to pursue an alternative source of supply for the Product.

12.      AMENDMENT TO EXHIBITS B AND C AND ADDITION OF NEW EXHIBIT F.  The
Agreement is hereby amended by replacing Exhibits B (In-Process Testing
Procedures and Specifications) and C (Product Release Test Methods and
Specifications) with Exhibits B-1 (CMC section of the Cubist U.S. NDA filing)
and C-1 (Master Product Specifications) attached hereto. To the extent that
there is any conflict between the specifications set forth in Exhibit C-1 and
those set forth in Exhibit B-1, the specifications set forth in Exhibit C-1
shall supersede in all respects.

         13. NO OTHER AMENDMENTS. Except to the extent amended hereby, all of
the definitions, terms, provisions and conditions set forth in the Agreement are
hereby ratified and confirmed and shall remain in full force and effect. The
terms and conditions herein and subject matter hereof shall at all times be
considered Confidential Information of Cubist, as defined in the Agreement. The
Agreement and this Amendment No. 2 shall be read and construed together as a
single agreement and the term "Agreement" shall be deemed a reference to the
Agreement as amended by this Amendment No. 2. This Amendment No. 2 may be signed
in any number of counterparts, each of which shall be deemed to be an original
and all of which together shall constitute but one and the same instrument. In
making proof of this Amendment No. 2 it shall not be necessary to produce or
account for more than one such counterpart.


<PAGE>


                                       7



         IN WITNESS  WHEREOF, this Amendment No. 2 has been executed under seal
by the parties hereto as of the day and year first above written.


                                 ACS DOBFAR SpA

                                 By: /s/ MARCO FELICIANI
                                    -------------------------------------
                                    Title:  President

                                 Date: 02/20/03


                                 CUBIST PHARMACEUTICALS, INC.

                                 By: /s/ MICHAEL W. BONNEY
                                    -------------------------------------
                                    Title:  President/COO

                                 Date: 2/13/03


</TEXT>
</DOCUMENT>
